Integra LifeSciences Reports First Quarter 2022 Financial Results
Integra LifeSciences Holdings Corporation (IART) reported Q1 2022 revenues of $376.6 million, a 4.6% increase year-over-year. GAAP earnings per diluted share declined to $0.39 from $0.53 in Q1 2021, while adjusted EPS rose to $0.74 from $0.69. The company raised its 2022 organic growth guidance from 3.5%-5% to 3.8%-5.2% and reaffirmed total revenue growth at 2.5%-3.5%. The gross margin improved to 62.1%. Cash flow from operations was $44 million, with net debt of $1.15 billion.
- Q1 2022 organic revenue growth of 5.6% exceeded expectations.
- Increased full-year organic growth guidance to 3.8%-5.2%.
- Improved gross margin of 62.1% from 59.5% year-over-year.
- Repurchased $125 million in shares and authorized an additional $225 million.
- GAAP earnings per diluted share decreased to $0.39 from $0.53 in Q1 2021.
- Uncertainty in global markets and ongoing supply constraints may affect growth.
PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2022.
First Quarter 2022 Highlights
- Revenues of
$376.6 million increased4.6% on a reported basis and5.6% on an organic basis compared to the prior year. - GAAP earnings per diluted share of
$0.39 , compared to$0.53 in the first quarter of 2021; adjusted earnings per diluted share of$0.74 , compared to$0.69 in the prior year. - The Company is raising its previous full-year 2022 organic growth guidance of
3.5% to5% to a new range of3.8% to5.2% , reflecting the better than expected first quarter revenue results. Reported revenue growth is reaffirmed at2.5% to3.5% . Adjusted earnings per share guidance range reaffirmed at$3.27 t o$3.35 .
“I am pleased with the resilience shown by Integra colleagues as we navigated the COVID-19 Omicron wave early in the quarter,” said Jan De Witte, Integra’s president and chief executive officer. “With global procedure volumes improving in March, our strong execution enabled us to deliver better-than-expected first quarter revenue with organic growth exceeding five percent.”
First Quarter 2022 Consolidated Performance
Total reported revenues of
The Company reported GAAP gross margin of
Adjusted EBITDA for the first quarter of 2022 was
The Company reported GAAP net income of
Adjusted net income for the first quarter of 2022 was
First Quarter 2022 Segment Performance
- Codman Specialty Surgical (
66% of Revenues)- Total revenues were
$247.3 million , representing reported growth of2.5% and organic growth of5.0% compared to the first quarter of 2021, driven by strength in Neurosurgery. Sales in the first quarter benefited from our recently launched CereLink® ICP Monitoring System, as well as a late quarter recovery in neurosurgery procedures.
- Total revenues were
- Tissue Technologies (
34% of Revenue)- Total revenues were
$129.3 million , representing reported growth of8.8% and organic growth of6.9% compared to the first quarter of 2021, driven by favorable timing in Private Label customer orders and growth in Wound Reconstruction and Care led by sales in our Integra® Dermal Matrices and SurgiMend®.
- Total revenues were
Strategic Initiatives and Key Developments
- Advancing key products
- NeuraGen® 3D, the Company's new peripheral nerve repair product, launched late in the first quarter. This innovative product is a nerve guide matrix designed to optimize the environment for nerve regeneration and may allow for more complete functional recovery following mid-gap nerve repair when compared to hollow nerve conduits alone.
- Following our U.S. and Europe launch of CereLink® in the third quarter of 2021, we expanded market coverage to Canada and Australia as well as several indirect markets through the first quarter.
- NeuraGen® 3D, the Company's new peripheral nerve repair product, launched late in the first quarter. This innovative product is a nerve guide matrix designed to optimize the environment for nerve regeneration and may allow for more complete functional recovery following mid-gap nerve repair when compared to hollow nerve conduits alone.
Balance Sheet, Cash Flow and Capital Allocation
The Company generated cash flow from operations of
As of quarter end, the Company had total liquidity of approximately
The Company completed the previously announced
In addition, on April 26, 2022, the Board of Directors authorized the Company to repurchase up to
2022 Outlook
For the second quarter 2022, the Company expects reported revenues in the range of
For the full year 2022, the Company is raising its organic growth expectations from an initial range of
Organic sales growth excludes acquisitions and divestitures as well as the effects of foreign currency and the year-over-year change in revenue from discontinued products. Organic growth includes ACell as of January 20, 2022.
Full year 2022 adjusted earnings per diluted share guidance is unchanged and is expected to be in a range of
The Company is providing forward-looking guidance regarding adjusted earnings per diluted share but is not providing a reconciliation to GAAP earnings per share, because certain GAAP expense items are highly variable, and management is unable to predict them with reasonable certainty and without unreasonable effort. Specifically, the financial impact and timing of divestitures, acquisitions, integrations, structural optimization and efforts to comply with the EU Medical Device Regulation are uncertain, depend on various dynamic factors and are not reasonably ascertainable at this time. These expense items could have a material impact on GAAP results. Adjusted earnings per diluted share also excludes the impact of intangible asset amortization associated with prior business acquisitions, which we expect to be approximately
Conference Call and Presentation Available Online
Integra has scheduled a conference call for 8:30 a.m. ET on Wednesday, April 27, 2022, to discuss first quarter 2022 financial results, and forward-looking financial guidance. The conference call will be hosted by Integra's senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question-and-answer session following the call. Integra's management team will reference a presentation during the conference call, which can be found on the Investor section of the website at investor.integralife.com.
Access to the live call is available by dialing (800) 289-0720 and using the passcode 5706502. A simultaneous webcast of the call will be available via the Company’s website at www.integralife.com. A webcast replay of the call can be accessed through the Investor Relations homepage of Integra's website at www.integralife.com. A replay of the call will be available until May 7, 2022 by dialing (888) 203-1112 and using the passcode 5706502.
About Integra
Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Aurora®, Bactiseal®, BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, Gentrix®, ICP Express®, Integra®, Licox® , MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen® , NeuraWrap™ , PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news and information about Integra and its products, please visit www.integralife.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” "forecast," "guidance," “plan,” “anticipate,” "target," or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning future financial performance, including projections for revenues, expected revenue growth (both reported and organic), GAAP and adjusted net income, GAAP and adjusted earnings per diluted share, non-GAAP adjustments such as divestiture, acquisition and integration-related charges, intangible asset amortization, structural optimization charges, EU Medical Device Regulation-related charges, and income tax expense (benefit) related to non-GAAP adjustments and other items, capital return plans and expectations and plans with respect to strategic initiatives and product development. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: the magnitude and duration of the COVID-19 pandemic and its effects on our employees, customers, patients, suppliers and distributors, including the economic impacts of the various recommendations, orders and protocols issued by governmental agencies and other regulatory bodies; the Company's ability to execute its operating plan effectively; the Company’s ability to successfully integrate acquired businesses; the Company’s ability to achieve sales growth in a timely fashion and execute on its channel reorganization in its Tissue Technologies segment; the Company's ability to manufacture and ship sufficient quantities of its products to meet its customers' demands; the ability of third-party suppliers to supply us with raw materials and finished products; global macroeconomic and political conditions; the Company's ability to manage its direct sales channels effectively; the sales performance of third-party distributors on whom the Company relies to generate revenue for certain products and geographic regions; the Company's ability to access and maintain relationships with customers of acquired entities and businesses; physicians' willingness to adopt and third-party payors' willingness to provide or maintain reimbursement for the Company's recently launched, planned and existing products; initiatives launched by the Company's competitors; downward pricing pressures from customers; the Company's ability to secure regulatory approval for products in development; the Company's ability to remediate quality systems violations; fluctuations in hospitals' spending for capital equipment; the Company's ability to comply with and obtain approvals for products of human origin and comply with regulations regarding products containing materials derived from animal sources; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, and control non-product costs; the Company’s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of divestiture, acquisition and integration-related costs; the geographic distribution of where the Company generates its taxable income; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the EU Medical Devices Regulation; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2021 and information contained in subsequent filings with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted free cash flow conversion. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures and discontinuances. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); and (v) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) intangible asset amortization expense; and (v) income tax impact from adjustments. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of free cash flow consists of GAAP net cash provided by operating activities less purchases of property and equipment.
Reconciliations of GAAP revenues to organic revenues and GAAP adjusted net income to adjusted EBITDA, and adjusted net income, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters ended March 31, 2022 and 2021, and the free cash flow and adjusted free cash flow conversion for the quarters ended March 31, 2022 and 2021, appear in the financial tables in this release.
The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.
Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
| (UNAUDITED) | |||||||
| (In thousands, except per share amounts) | |||||||
| Three Months Ended March 31, | |||||||
| 2022 | 2021 | ||||||
| Total revenues, net | $ | 376,638 | $ | 360,071 | |||
| Costs and expenses: | |||||||
| Cost of goods sold | 142,569 | 145,823 | |||||
| Research and development | 24,085 | 22,374 | |||||
| Selling, general and administrative | 159,926 | 156,633 | |||||
| Intangible asset amortization | 3,894 | 4,527 | |||||
| Total costs and expenses | 330,474 | 329,357 | |||||
| Operating income | 46,164 | 30,714 | |||||
| Interest income | 1,377 | 1,748 | |||||
| Interest expense | (11,655 | ) | (12,929 | ) | |||
| Gain from sale of business | — | 42,876 | |||||
| Other income, net | 3,429 | 4,869 | |||||
| Income before income taxes | 39,315 | 67,278 | |||||
| Income tax expense | 6,414 | 21,884 | |||||
| Income from continuing operations | |||||||
| Net income | $ | 32,901 | $ | 45,394 | |||
| Net income per share: | |||||||
| Diluted net income per share | |||||||
| Weighted average common shares outstanding for diluted net income per share | 84,276 | 85,258 | |||||
The following table presents revenues disaggregated by the major sources for the three months ended March 31, 2022 and 2021 (amounts in thousands):
| Three Months Ended March 31, | |||||||
| 2022 | 2021 | Change | |||||
| Neurosurgery | 194,675 | 189,254 | |||||
| Instruments | 52,633 | 51,987 | |||||
| Total Codman Specialty Surgical | 247,308 | 241,241 | |||||
| Wound Reconstruction and Care | 94,630 | 88,698 | |||||
| Private Label | 34,700 | 30,132 | |||||
| Total Tissue Technologies | 129,330 | 118,830 | |||||
| Total reported revenues | 376,638 | 360,071 | |||||
| Impact of changes in currency exchange rates | 4,608 | ||||||
| Less contribution of revenues from acquisitions | (2,715 | ) | — | ||||
| Less contribution of revenues from divested products | (814 | ) | (169 | ) | |||
| Less contribution of revenues from discontinued products | (2,317 | ) | (4,485 | ) | |||
| Total organic revenues(1) | $ | 375,400 | $ | 355,417 | |||
(1) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products.
Items included in GAAP net income and location where each item is recorded are as follows:
| (In thousands) | |||||||||||
| Three Months Ended March 31, 2022 | |||||||||||
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort.(d) | OI&E(e) | Tax(f) | ||||
| Acquisition, divestiture and integration-related charges(1) | 574 | 854 | 2,077 | (1,065 | ) | — | (1,292 | ) | — | ||
| Structural Optimization charges | 6,320 | 2,932 | 3,294 | 94 | — | — | — | ||||
| EU Medical Device Regulation charges | 9,513 | 744 | 3,531 | 5,238 | — | — | — | ||||
| Intangible asset amortization expense | 20,094 | 16,200 | — | — | 3,894 | — | — | ||||
| Estimated income tax impact from above adjustments and other items | (7,422 | ) | — | — | — | — | — | (7,422 | ) | ||
| Depreciation expense | 9,591 | — | — | — | — | — | |||||
a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses.
Items included in GAAP net income and location where each item is recorded are as follows:
| (In thousands) | |||||||
| Three Months Ended March 31, 2021 | |||||||
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort.(d) | OI&E(e) | Tax(f) |
| Acquisition, divestiture and integration-related charges(1) | (27,001) | 8,047 | 7,837 | 1,578 | — | (44,463) | — |
| Structural Optimization charges | 3,979 | 1,868 | 1,571 | 540 | — | — | — |
| EU Medical Device Regulation charges | 5,748 | 264 | 2,086 | 3,398 | — | — | — |
| Intangible asset amortization expense | 22,541 | — | — | — | 22,541 | — | — |
| Estimated income tax impact from above adjustments and other items | (8,362) | — | — | — | — | — | (8,362) |
| Depreciation expense | 9,427 | — | — | — | — | — | — |
a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses. The Company completed the sales of its Extremity Orthopedics business and recognized a gain of
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO ADJUSTED EBITDA | |||||||
| (UNAUDITED) | |||||||
| (In thousands) | |||||||
| Three Months Ended March 31, | |||||||
| 2022 | 2021 | ||||||
| GAAP net income | 32,901 | 45,394 | |||||
| Non-GAAP adjustments: | |||||||
| Depreciation and intangible asset amortization expense | 29,685 | 31,968 | |||||
| Other (income) expense, net | (2,136 | ) | (3,282 | ) | |||
| Interest expense, net | 10,278 | 11,181 | |||||
| Income tax expense | 6,414 | 21,884 | |||||
| Structural optimization charges | 6,320 | 3,979 | |||||
| EU Medical Device Regulation charges | 9,513 | 5,748 | |||||
| Acquisition, divestiture and integration-related charges(1) | 574 | (27,001 | ) | ||||
| Total of non-GAAP adjustments | 60,648 | 44,477 | |||||
| Adjusted EBITDA | $ | 93,548 | $ | 89,871 | |||
(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses.
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE | |||||||
| (UNAUDITED) | |||||||
| (In thousands, except per share amounts) | |||||||
| Three Months Ended March 31, | |||||||
| 2022 | 2021 | ||||||
| GAAP net income | 32,901 | 45,394 | |||||
| Non-GAAP adjustments: | |||||||
| Structural optimization charges | 6,320 | 3,979 | |||||
| Acquisition, divestiture and integration-related charges(1) | 574 | (27,001 | ) | ||||
| EU Medical Device Regulation charges | 9,513 | 5,748 | |||||
| Intangible asset amortization expense | 20,094 | 22,541 | |||||
| Estimated income tax impact from adjustments and other items | (7,422 | ) | 8,362 | ||||
| Total of non-GAAP adjustments | 29,079 | 13,629 | |||||
| Adjusted net income | $ | 61,980 | $ | 59,023 | |||
| Adjusted diluted net income per share | $ | 0.74 | $ | 0.69 | |||
| Weighted average common shares outstanding for diluted net income per share | 84,276 | 85,258 | |||||
(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses.
| CONDENSED BALANCE SHEET DATA | |||||
| (UNAUDITED) | |||||
| (In thousands) | |||||
| March 31, 2022 | December 31, 2021 | ||||
| Cash and cash equivalents | $ | 407,092 | $ | 513,448 | |
| Trade accounts receivable, net | 234,010 | 231,831 | |||
| Inventories, net | 328,005 | 317,386 | |||
| Current and long-term borrowing under senior credit facility | 869,772 | 869,257 | |||
| Borrowings under securitization facility | 112,000 | 112,500 | |||
| Long-term convertible securities | 565,155 | 564,426 | |||
| Stockholders' equity | $ | 1,615,197 | $ | 1,684,804 | |
| CONDENSED STATEMENT OF CASH FLOWS | |||||||
| (UNAUDITED) | |||||||
| (In thousands) | |||||||
| Three Months Ended March 31, | |||||||
2022 | 2021 | ||||||
| Net cash provided by operating activities | $ | 44,344 | $ | 69,081 | |||
| Net cash used in investing activities | (14,067 | ) | (117,566 | ) | |||
| Net cash used by financing activities | (133,465 | ) | (3,015 | ) | |||
| Effect of exchange rate changes on cash and cash equivalents | (3,168 | ) | (9,690 | ) | |||
| Net decrease in cash and cash equivalents | $ | (106,356 | ) | $ | (61,190 | ) | |
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO MEASURES OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION | ||||||
| (UNAUDITED) | ||||||
| (In thousands) | ||||||
| Three Months Ended March 31, | ||||||
| 2022 | 2021 | |||||
| Net cash provided by operating activities | $ | 44,344 | $ | 69,087 | ||
| Purchases of property and equipment | (9,325 | ) | (6,675 | ) | ||
| Free cash flow | 35,019 | 62,412 | ||||
| Adjusted net income(1) | $ | 61,980 | $ | 59,023 | ||
| Adjusted free cash flow conversion | 56.5 | % | 105.7 | % | ||
| Twelve Months Ended March 31, | ||||||
| 2022 | 2021 | |||||
| Net cash provided by operating activities | $ | 287,681 | $ | 252,102 | ||
| Purchases of property and equipment | (50,672 | ) | (29,045 | ) | ||
| Free cash flow | 237,009 | 223,057 | ||||
| Adjusted net income(1) | $ | 274,649 | $ | 226,343 | ||
| Adjusted free cash flow conversion | 86.3 | % | 98.6 | % | ||
(1) Adjusted net income for quarters ended March 31, 2022 and 2021 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations.
The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.
FAQ
What were Integra LifeSciences' earnings results for Q1 2022?
What is the revenue guidance for Integra LifeSciences for 2022?
What are the organic growth expectations for Integra LifeSciences in 2022?
How much cash flow did Integra generate in Q1 2022?
What is Integra LifeSciences' plan for share repurchase?
